BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 8791046)

  • 1. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
    Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
    Eur Urol; 1996; 29(4):407-12. PubMed ID: 8791046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PSA in prostatic fluid].
    Lehmann K; Simmler F; Schmucki O; Hauri D
    Urologe A; 1994 May; 33(3):232-4. PubMed ID: 7519804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml.
    Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
    J Urol; 1997 Jan; 157(1):185-8. PubMed ID: 8976247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
    Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
    J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
    Bare R; Hart L; McCullough DL
    Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation of IL-8 and IL-6 in prostatic fluid with serum prostate-specific antigen level in patients with benign prostatic hyperplasia complicated by prostatitis].
    Ren X; Wu C; Yu Q; Zhu F; Liu P; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jan; 36(1):135-9. PubMed ID: 26806754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
    Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
    Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
    Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
    Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasia.
    Scattoni V; Raber M; Montorsi F; Da Pozzo L; Brausi M; Calori G; Freschi M; Rigatti P
    Eur Urol; 1999 Dec; 36(6):621-30. PubMed ID: 10559617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
    Agarwal DK; Costello AJ; Peters J; Sikaris K; Crowe H
    BJU Int; 2000 Apr; 85(6):690-5. PubMed ID: 10759667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.